Myriad, the Web3 prediction and trading protocol, has surpassed $10M in USDC trading volume and 511K users, signaling the rise of prediction markets.Myriad, the Web3 prediction and trading protocol, has surpassed $10M in USDC trading volume and 511K users, signaling the rise of prediction markets.

Prediction Protocol Myriad Hits $10M Milestone With 511K Users Onboarded

myriad

Myriad, a Web3 prediction and trading protocol, announced today that it has surpassed $10 million in USDC trading volume since launch and onboarded more than 511,000 users. The team says that the milestone underlines rapid adoption and the project’s ambition to make prediction markets a core part of decentralized finance.

Since going live, Myriad has facilitated more than 5.4 million predictions and seen its browser extension installed over 60,000 times. Those early traction numbers have pushed the platform quickly into the upper ranks of Web3 trading applications, the company said, while it continues to foreground a mission of “making information itself a tradable asset class.”

“Financial markets have always been about speculation, but Myriad is turning speculation into a product,” said Loxley Fernandes, co-founder and CEO of Myriad. “We’re showing that trading ideas and forecasts is not only possible, it’s the next frontier for capital markets. Myriad is building the rails for prediction markets to evolve beyond a niche crypto product and become an entirely new segment of DeFi.”

Built on a media-driven lineage, tracing its roots to Decrypt and Rug Radio, Myriad’s ethos leans on journalistic credibility as a trust anchor for a market that trades on expectations and consensus. That heritage, the company argues, has helped fuel early momentum among retail users and projects that want prediction primitives baked into products.

The appeal of prediction markets extends beyond crypto-native investors. Noted market figures have suggested the format’s long-term potential: Thomas Peterffy, founder of Interactive Brokers, has predicted that prediction markets could surpass the stock market within 15 years, pointing to their capacity to price real-world expectations and consensus.

From Consumer App to B2B Rails

Myriad is positioning itself as both a consumer-facing product and a business-to-business protocol for other prediction applications. It has already been deployed on Abstract and Linea and plans further integrations with EigenLayer and EigenCloud. The roadmap zeroes in on multichain expansion, smarter oracle integrations and U.S. regulatory alignment.

It is a clear sign that the team is gearing up for institutional adoption as the platform scales. On the tech side, Myriad is building blended oracles to shore up data integrity and sketching out ERC-PRED, a proposed token standard meant to serve as the common unit for prediction markets; if it catches on, ERC-PRED could standardize prediction assets and make them interoperable across protocols and chains.

Alongside product and technical initiatives, Myriad emphasizes a compliance-first expansion strategy. That posture is intended to bridge the regulatory gap that has kept some institutional players on the sidelines of on-chain markets, and to accelerate mainstream adoption by offering clarity and controls that enterprise partners expect.

The company says its approach couples “retail adoption with enterprise-grade infrastructure,” showing a hybrid strategy that leans on media-led trust while building the plumbing institutions require. Prediction markets trade on information: forecasts, polls, economic data, and even binary event outcomes. Proponents argue that markets that aggregate diverse opinions can surface more accurate forecasts than any single analyst, and that monetizing those forecasts creates incentives for better information discovery.

Myriad’s early metrics, half a million-plus users and millions of predictions, suggest a meaningful appetite for these mechanics among Web3 participants. Whether prediction markets can scale to rival legacy financial instruments will depend on regulatory clarity, institutional tooling, and the ability of protocols to deliver reliable oracle data and interoperable asset standards.

With strong early traction, media-driven credibility, and a public roadmap that mixes technical innovation with compliance work, Myriad is charting a course to make prediction markets a recognized pillar of global DeFi. The project’s next chapters will test whether its blend of consumer product, B2B rails, and standardized prediction assets can move the sector from niche experiment to mainstream market infrastructure.

Market Opportunity
RISE Logo
RISE Price(RISE)
$0.005918
$0.005918$0.005918
-2.05%
USD
RISE (RISE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23